Northwest Biotherapeutics Reports $3.1M Net Loss in Q1 2026, Improved Financial Position

Northwest Biotherapeutics, Inc. reported a net loss of $3.1 million for the first quarter of 2026, a significant improvement compared to a net loss of $19.3 million during the same period in 2025. The company generated total revenues of $494,000, up from $375,000 in the prior year. This increase in revenue is attributed to ongoing research activities and other income sources, including a $2.25 million settlement gain related to litigation. Operating costs and expenses decreased to $11.4 million from $17.7 million, primarily due to reduced research and development expenses, which fell to $4.9 million from $8.4 million, reflecting lower costs associated with the Marketing Authorization Application (MAA) process for its DCVax®-L product.

In terms of financial position, Northwest Biotherapeutics reported total assets of $80.1 million as of March 31, 2026, a slight decrease from $81.3 million at the end of 2025. Current liabilities decreased to $83.0 million from $91.7 million, largely due to a reduction in convertible notes and other financial obligations. The company’s stockholders’ deficit improved to $50.5 million from $60.3 million, indicating a positive shift in its financial health. The company continues to face challenges related to liquidity, as it has incurred annual net operating losses since inception and relies on equity and debt financing to fund operations.

Strategically, Northwest Biotherapeutics has made significant progress in its clinical and operational activities. The company is actively engaged in the MAA review process for its DCVax®-L product, which is designed to treat glioblastoma. Additionally, the company has established a clinic arrangement with the London Welbeck Hospital to enhance its operational capacity in the UK. The buildout of this facility is expected to be completed by June 2026. Furthermore, the company is exploring the development of a second DCVax production operation in the UK and has made strides in establishing manufacturing capabilities in the US for both its DCVax and aDC1 products.

Looking ahead, Northwest Biotherapeutics anticipates continued operational challenges as it seeks to secure additional funding to support its ongoing research and development efforts. The company has expressed substantial doubt about its ability to continue as a going concern for at least one year from the date of the filing, emphasizing the need for further capital to sustain operations until it can generate significant revenue. The company plans to pursue various financing options, including equity and debt, to address its liquidity needs and support its strategic initiatives.